241 related articles for article (PubMed ID: 20487426)
1. Clinical characteristics and treatment outcome of patients with visceral leishmaniasis and HIV co-infection in northwest Ethiopia.
Hurissa Z; Gebre-Silassie S; Hailu W; Tefera T; Lalloo DG; Cuevas LE; Hailu A
Trop Med Int Health; 2010 Jul; 15(7):848-55. PubMed ID: 20487426
[TBL] [Abstract][Full Text] [Related]
2. Concordant HIV infection and visceral leishmaniasis in Ethiopia: the influence of antiretroviral treatment and other factors on outcome.
ter Horst R; Collin SM; Ritmeijer K; Bogale A; Davidson RN
Clin Infect Dis; 2008 Jun; 46(11):1702-9. PubMed ID: 18419422
[TBL] [Abstract][Full Text] [Related]
3. [Visceral leishmaniasis: a comparative study of patients with and without human immunodeficiency virus infection].
Reus S; Sánchez R; Portilla J; Boix V; Priego M; Merino E; Román F
Enferm Infecc Microbiol Clin; 1999 Dec; 17(10):515-20. PubMed ID: 10650648
[TBL] [Abstract][Full Text] [Related]
4. A comparison of miltefosine and sodium stibogluconate for treatment of visceral leishmaniasis in an Ethiopian population with high prevalence of HIV infection.
Ritmeijer K; Dejenie A; Assefa Y; Hundie TB; Mesure J; Boots G; den Boer M; Davidson RN
Clin Infect Dis; 2006 Aug; 43(3):357-64. PubMed ID: 16804852
[TBL] [Abstract][Full Text] [Related]
5. Leishmaniases and HIV/AIDS co-infections: review of common features and management experiences.
Ali A
Ethiop Med J; 2002 Apr; 40 Suppl 1():37-49. PubMed ID: 12802830
[TBL] [Abstract][Full Text] [Related]
6. Clinical and epidemiological features of visceral leishmaniasis and HIV co-infection in fifteen patients from Brazil.
Daher EF; Fonseca PP; Gerhard ES; Leitão TM; Silva Júnior GB
J Parasitol; 2009 Jun; 95(3):652-5. PubMed ID: 19642802
[TBL] [Abstract][Full Text] [Related]
7. [Visceral leishmaniasis and HIV infection in the HAART era].
Marques N; Cabral S; Sá R; Coelho F; Oliveira J; Saraiva da Cunha JG; Meliço Silvestre A
Acta Med Port; 2007; 20(4):291-8. PubMed ID: 18198072
[TBL] [Abstract][Full Text] [Related]
8. Safety and effectiveness of meglumine antimoniate in the treatment of Ethiopian visceral leishmaniasis patients with and without HIV co-infection.
Hailu W; Weldegebreal T; Hurissa Z; Tafes H; Omollo R; Yifru S; Balasegaram M; Hailu A
Trans R Soc Trop Med Hyg; 2010 Nov; 104(11):706-12. PubMed ID: 20870258
[TBL] [Abstract][Full Text] [Related]
9. [Visceral leishmaniasis in patients with HIV infection].
Ribera E; Cucurull E; Ocaña I; Vallespí T; Gasser I; Juste C
Enferm Infecc Microbiol Clin; 1995 Feb; 13(2):73-9. PubMed ID: 7711130
[TBL] [Abstract][Full Text] [Related]
10. [The clinical and evolutional characteristics of visceral leishmaniasis in patients with HIV infection].
Delgado Fernández M; García Ordoñez MA; Martos Pérez F; Reguera Iglesias JM; Jiménez Oñate F; Colmenero Castillo JD
An Med Interna; 1997 Oct; 14(10):506-10. PubMed ID: 9424140
[TBL] [Abstract][Full Text] [Related]
11. Limited effectiveness of high-dose liposomal amphotericin B (AmBisome) for treatment of visceral leishmaniasis in an Ethiopian population with high HIV prevalence.
Ritmeijer K; ter Horst R; Chane S; Aderie EM; Piening T; Collin SM; Davidson RN
Clin Infect Dis; 2011 Dec; 53(12):e152-8. PubMed ID: 22016502
[TBL] [Abstract][Full Text] [Related]
12. Cutaneous leishmaniasis associated with visceral leishmaniasis in a case of acquired immunodeficiency syndrome (AIDS).
Pourahmad M; Hooshmand F; Rahiminejad M
Int J Dermatol; 2009 Jan; 48(1):59-61. PubMed ID: 19126052
[TBL] [Abstract][Full Text] [Related]
13. HIV/AIDS-related visceral leishmaniasis: a clinical and epidemiological description of visceral leishmaniasis in northern Brazil.
Albuquerque LC; Mendonça IR; Cardoso PN; Baldaçara LR; Borges MR; Borges Jda C; Pranchevicius MC
Rev Soc Bras Med Trop; 2014; 47(1):38-46. PubMed ID: 24603735
[TBL] [Abstract][Full Text] [Related]
14. Central role of interleukin-15 in human immunodeficiency virus (HIV)-infected patients with visceral leishmaniasis.
d'Ettorre G; Ceccarelli G; Carnevalini M; Forcina G; Zaffiri L; Massetti AP; Mastroianni CM; Vullo V
Acta Trop; 2006 Aug; 99(1):83-7. PubMed ID: 16962979
[TBL] [Abstract][Full Text] [Related]
15. Field evaluation of rK39 test and direct agglutination test for diagnosis of visceral leishmaniasis in a population with high prevalence of human immunodeficiency virus in Ethiopia.
ter Horst R; Tefera T; Assefa G; Ebrahim AZ; Davidson RN; Ritmeijer K
Am J Trop Med Hyg; 2009 Jun; 80(6):929-34. PubMed ID: 19478251
[TBL] [Abstract][Full Text] [Related]
16. Parasite susceptibility to amphotericin B in failures of treatment for visceral leishmaniasis in patients coinfected with HIV type 1 and Leishmania infantum.
Lachaud L; Bourgeois N; Plourde M; Leprohon P; Bastien P; Ouellette M
Clin Infect Dis; 2009 Jan; 48(2):e16-22. PubMed ID: 19093811
[TBL] [Abstract][Full Text] [Related]
17. Leishmania / HIV co-infections.
Desjeux P
Afr Health; 1995 Nov; 18(1):20-2. PubMed ID: 12290565
[TBL] [Abstract][Full Text] [Related]
18. The initial effectiveness of liposomal amphotericin B (AmBisome) and miltefosine combination for treatment of visceral leishmaniasis in HIV co-infected patients in Ethiopia: A retrospective cohort study.
Abongomera C; Diro E; de Lima Pereira A; Buyze J; Stille K; Ahmed F; van Griensven J; Ritmeijer K
PLoS Negl Trop Dis; 2018 May; 12(5):e0006527. PubMed ID: 29799869
[TBL] [Abstract][Full Text] [Related]
19. [Intestinal parasitic infections and leishmaniasis in patients with HIV infection].
Moreno-Camacho A; López-Vélez R; Muñoz Sanz A; Labarga-Echevarría P
Enferm Infecc Microbiol Clin; 1998; 16 Suppl 1():52-60. PubMed ID: 9859620
[TBL] [Abstract][Full Text] [Related]
20. Visceral leishmaniasis: another HIV-associated opportunistic infection? Report of eight cases and review of the literature.
Altés J; Salas A; Riera M; Udina M; Galmés A; Balanzat J; Ballesteros A; Buades J; Salvá F; Villalonga C
AIDS; 1991 Feb; 5(2):201-7. PubMed ID: 2031693
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
